News

SBRI Healthcare has unveiled six UK companies in line for an award of up to £1 million each to help advance their products addressing a range of healthcare challenges.

The UK’s Medical Research Council has announced a ‘rapid response’ call for research applications centred on the Zika virus, as the infection continues to spread at an alarming rate.

Takeda and Lundbeck will by relieved by news that FDA advisors are backing the effectiveness of their antidepressant Brintellix for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

AstraZeneca said it has delivered a strong pipeline and financial performance in 2015, but also warned of tougher times ahead with a low to mid single-digit percentage drop in sales and earnings on the horizon.

A new global hub for cancer research and treatment is set to be established in London with the aim of accelerating the discovery of new treatments.

Patients in Europe with a certain form of lung cancer could soon get access to a new, first-in-class treatment option after regulators waved through AstraZeneca’s targeted therapy Tagrisso.

Teva has teamed up with Canadian biotech AbCellera for the discovery of rare monoclonal antibodies, using AbCellera’s high-throughput single cell antibody platform. This marks the second such deal for the Canadian firm in the space of a week.

The US has reported the first case of the Zika virus being transmitted sexually, further raising fears over the potential spread of the disease.

GlaxoSmithKline has expanded its alliance with Adaptimmune Therapeutics to accelerate its lead clinical cancer programme toward pivotal trials in synovial sarcoma.

Cambridge, UK-based drug discovery and development group Mission Therapeutics has raised £60 million from investors and existing shareholders to help drive advances in its key therapeutic programmes.

Health Education England (HEE) has announced a new scheme that will pay £20,000 to GP trainees who commit to working in the least sought after areas of the country.

Pfizer has booked sales of $14 billion for the fourth quarter, marking a rise of 7% over the year-ago period, as operational growth of 14% was reigned in by currency exchange rate effects. 

Sanofi Pasteur has announced that it is developing a vaccine for the Zika virus, which is spreading rapidly across the Americas.

Abbott is delving deeper into diagnostics with a definitive deal to buy test-maker Alere for around $5.8 billion.

Cost regulators for the National Health Service in England and Wales have expanded treatment options for patients with ankylosing spondylitis.